The company is in the process of being taken private by Sycamore Partners in a deal that is expected to close in the fourth quarter of this year.

Cencora, Inc. COR is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. Shares of this Zacks Rank #2 (Buy) ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cencora (COR – Research Report) and Johnson ...

Walgreens Cashes In: Slashes Cencora Stake Again In Debt-Fighting Move ...

BofA analyst Allen Lutz raised the firm’s price target on Cencora (COR) to $285 from $270 and keeps a Neutral rating on the shares. The recent ...

Renewed collaborations with Express Scripts and Walgreens strengthen core distribution capabilities and align resources to meet customer needs effectively. Cencora operates in a highly competitive ...